Physician profile
Robert C Pyle
NPI 1093870313
$10,580.18
in general payments reported to CMS, 2019-2025
52 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,103 · 2020: $1,180 · 2021: $759 · 2022: $2,507 · 2023: $2,239 · 2024: $1,668 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,031.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,389.77 | 2020-2024 | |
| Lilly USA, LLC | $985.36 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $917.97 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $679.14 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $647.01 | 2019-2024 | |
| Amgen INC. | $521.23 | 2019-2024 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $496.72 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $448.38 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.93 | 2019-2023 | Jardiance |
| Allergan, INC. | $411.39 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $327.58 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $238.15 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.75 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $226.51 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $179.54 | 2022-2023 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.